The growing case for stainless steel versus single-use in mRNA vaccine production

Live30 webinars are thirty-minute presentations designed toupdate you on the latest innovations, applications, and data in a fast yetinteractive format.

As mRNA vaccine production matures into a post-pandemic world, and timelines stretch out, the industry will need to consider whether stainless steel manufacturing equipment provides a better solution than the single-use equipment currently dominating the landscape. As supply chains settle, the price volatility and limited availability of stainless steel are less of a concern, and in many cases, stainless steel may offer a significantly better overall return on investment (ROI).

• Pros and cons of single-use vs stainless steel in mRNA vaccine production
• Case studies of straightforward tech transfer into stainless steel unit operations
• Insight into the pricing and lead times of stainless steel equipment currently
• Example ROI calculations demonstrating net benefit to manufacturing companies

Steve Attig

Fellow – Bioprocess Design at CRB

Steve Attig is a Fellow, Bioprocess Design, with more than 25 years of experience in process engineering, project management and operations. He focuses on and biotechnology applications. His broad and deep experience allows for rapid execution of pre-feasibility studies for startups, and mid- and large-scale pharma clients looking for early cost and facility design implications.

Watch now

SPEAKERS

Steve Attig

Fellow – Bioprocess Design at CRB

You might also like

The benefits of single-use systems for enhanced process security

Eoin Dolan

4 September

Watch

Streamlining immune cell therapy manufacturing workflows with single-use cytokines

Gabriella Perell

19 June

Watch

Enhancing mRNA production with advanced analytics: WACKER Biotech

Michael Daume, Blaz Bakalar

8 October

Watch

Scalable chromatographic strategies for mRNA and saRNA purification from IVT

Tomas Kostelec

29 February

Watch

Trends in innovation for downstream process intensification, product yield, single-use closed systems, and gentle ATMP bioprocessing: a KOL panel discussing 2024 insights in gene therapy manufacturing

Rachel Legmann, Andrew Tustian

27 February

Watch